Company Filing History:
Years Active: 2006
Title: Thomas H. Marsilje: Innovator in Pharmaceutical Compounds
Introduction
Thomas H. Marsilje is a notable inventor based in the United States. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that modulate various biological activities. Although he currently holds no patents, his work has the potential to impact medical treatments significantly.
Latest Patents
Marsilje's latest inventions include "Compounds and Compositions for Modulating EGFR Activity." This invention provides compounds and pharmaceutical compositions that are useful for modulating EGFR activity. It also outlines methods for using these compounds to treat, ameliorate, or prevent conditions associated with abnormal or deregulated EGFR activity. Another notable invention is "Compounds and Compositions as Protein Kinase Inhibitors." This invention presents novel pyrimidine and pyridine derivatives, along with pharmaceutical compositions, that can be used to treat conditions responding to the inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
Career Highlights
Marsilje is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis focuses on innovative solutions in drug development, particularly in the area of targeted therapies.
Collaborations
Some of his notable coworkers include Pierre-Yves Michellys and Wei Pei. Their collaborative efforts contribute to the advancement of pharmaceutical research and development.
Conclusion
Thomas H. Marsilje is an influential figure in the pharmaceutical industry, with a focus on developing innovative compounds for medical applications. His contributions, although not yet reflected in patents, hold promise for future advancements in treatment methodologies.